Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Eplivanserin

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Eplivanserin
Clinical data
Routes of
administration
Oral
ATC code
  • none
Identifiers
  • (Z,E)-1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-2-propen-1-one O-[2-(dimethylamino)ethyl]oxime
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
CompTox Dashboard(EPA)
ECHA InfoCard100.189.857Edit this at Wikidata
Chemical and physical data
FormulaC19H21FN2O2
Molar mass328.387 g·mol−1
3D model (JSmol)
  • c2cc(O)ccc2\C=C\C(=N\OCCN(C)C)\c1ccccc1F
  • InChI=1S/C19H21FN2O2/c1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15/h3-12,23H,13-14H2,1-2H3/b12-9+,21-19- ☒N
  • Key:VAIOZOCLKVMIMN-PRJWTAEASA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Eplivanserin (SR-46,349; planned trade nameCiltyri) was an experimental drug for the treatment ofinsomnia which was being developed bySanofi Aventis.[1]

Sanofi Aventis announced in December 2009 that it was withdrawing its application for approval of eplivanserin from both theU.S. Food and Drug Administration and theEuropean Medicines Agency.[2]

Mechanism of action

[edit]

Eplivanserin is aninverse agonist on theserotonin receptor subtype5-HT2A. In contrast to oldersedating drugs acting on 5-HT2A receptors (e.g.,mirtazapine,clozapine,risperidone), eplivanserin has practically no affinity todopamine,histamine andadrenergic receptors.[3]

The drug has been shown toupregulate 5-HT2A receptor expression, unlike many known 5-HT2Aantagonists, which paradoxically induce receptordownregulation.[4][5]

Study results

[edit]

In a placebo controlledPhase II clinical trial with 351 subjects, eplivanserin reduced the sleep latency by 39 minutes (versus 26 minutes under placebo).[3]

Synthesis

[edit]
Patent:[6]Chinese

The condensation between 2'-Fluoroacetophenone [445-27-2] (5) &4-hydroxybenzaldehyde [123-08-0] (6) give a chalcone intermediate (also an enone), i.e.CID:53982926 (7).

(2-chloroethyl)dimethylamine (CDMA) &acetone oxime are reacted together to give dimethylaminoacetoxime (DMA acetoxime),CID:16641114 (3).

Convergent synthesis gives the product as a mixture of isomers.

See also

[edit]

References

[edit]
  1. ^"Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD".Neurotransmitter.net.
  2. ^Spencer M, Berton E (21 December 2009)."Sanofi-Aventis Discontinues Eplivanserin For Insomnia". Dow Jones & Co. Archived fromthe original on 21 July 2011. Retrieved27 January 2010.
  3. ^abTeegarden BR, Al Shamma H, Xiong Y (2008). "5-HT(2A) inverse-agonists for the treatment of insomnia".Current Topics in Medicinal Chemistry.8 (11):969–76.doi:10.2174/156802608784936700.PMID 18673166.
  4. ^Rinaldi-Carmona M, Congy C, Simiand J, Oury-Donat F, Soubrie P, Breliere JC, Le Fur G (January 1993). "Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain".Molecular Pharmacology.43 (1):84–89.doi:10.1016/S0026-895X(25)13451-2.PMID 8423772.
  5. ^Yadav PN, Kroeze WK, Farrell MS, Roth BL (October 2011)."Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo".The Journal of Pharmacology and Experimental Therapeutics.339 (1):99–105.doi:10.1124/jpet.111.183780.PMC 3186284.PMID 21737536.
  6. ^Eric Garcia, Christian Hoff,U.S. patent 20,120,022,292 (2012 to Sanofi-Aventis).
GABAA
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Imidazoles
Monoureides
Neurosteroids
Nonbenzodiazepines
Phenols
Piperidinediones
Quinazolinones
Others
GABAB
H1
Antihistamines
Antidepressants
Antipsychotics
α2-Adrenergic
5-HT2A
Antidepressants
Antipsychotics
Others
Melatonin
Orexin
α2δVDCC
Others
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Stub icon

Thissedative-related article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Eplivanserin&oldid=1307138989"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp